Neurotology

Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology

Retrieved on: 
Wednesday, August 30, 2023
Ménière's disease, Disease, Neurotology, Clinical trial, Investigational New Drug, Acquisition, Collection, Patient, SAN, Therapy, IND, Safety, Pharmaceutical industry, Spiral

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.
  • As part of this financing, Spiral welcomes the addition of Dean Slagel, Managing Director of Esperante Ventures, to its Board of Directors.
  • Last year Spiral completed enrollment of an open label clinical study of SPT-2101 in patients with Meniere's Disease.
  • With the recent acquisition of Otonomy assets and our growing therapeutic pipeline, we are positioning Spiral as a forerunner in the field."

IOTAMOTION COMPLETES $12M SERIES A RAISE TO ACCELERATE COMMERCIAL EXPANSION OF IOTASOFT® INSERTION SYSTEM

Retrieved on: 
Wednesday, July 26, 2023
Neurotology, Inc., Surgeon, University, Research Corporation, RCT, Coronavirus Scientific Advisory Board, Research, Multimedia, Doctor of Philosophy, Marketing, IOWA, Patient, Entrepreneurship, Growth, Renewable energy, Medical device, MD

The company closed the round with support from a select group of venture capital firms, private investors, and current shareholders.

Key Points: 
  • The company closed the round with support from a select group of venture capital firms, private investors, and current shareholders.
  • The lead investor was Research Corporation Technologies, Inc. (RCT) with participation from Mutual Capital Partners, ISA Ventures, and Next Level Ventures.
  • The capital raised in the Series A round will fuel commercial expansion of the iotaSOFT® Insertion System, which continued to gain momentum in the first half of 2023, and drive new innovations in robotic-assisted cochlear implantation.
  • iotaMotion continues to drive adoption of the iotaSOFT Insertion System through an expanded commercial release with systems distributed across the country.

Renowned Surgeon, Researcher, and Educator in Robotic Surgery of the Head and Neck Joins NYU Langone Health as New Chair of Otolaryngology

Retrieved on: 
Thursday, June 29, 2023
University, Moses Austin, Neurotology, NYU, New York University Grossman School of Medicine, Neurofibromatosis, Human, Research, Doctor of Philosophy, Neck, Bangladesh Technical Education Board, NYU Langone Health, University of Pittsburgh Medical Center, Cell biology, Patent, Patient, Division, Veterans' affairs, MD Anderson Cancer Center, Paralysis, Wilfrid Sellars, NIH, Dentistry, Nursing, Head, MD, Otorhinolaryngology

He joins the institution from the University of Pittsburgh School of Medicine, where he served as a professor in the Departments of Otolaryngology and Cell Biology, director of robotic surgery in the Division of Head and Neck Surgery, and co-leader of the Head and Neck Cancer Program.

Key Points: 
  • He joins the institution from the University of Pittsburgh School of Medicine, where he served as a professor in the Departments of Otolaryngology and Cell Biology, director of robotic surgery in the Division of Head and Neck Surgery, and co-leader of the Head and Neck Cancer Program.
  • Dr. Duvvuri has made significant innovations in the field of head and neck surgery , advancing robotic surgery to perform complex and precise procedures that simultaneously minimize patient impact.
  • Dr. Duvvuri holds a patent on a novel tactile feedback system for robotic surgery.
  • "An innovator in the field of head and neck surgery, Dr. Duvvuri has significantly advanced robotic surgery to perform complex and precise procedures that maximize patient outcomes while lessening detrimental side effects," said Robert I. Grossman, MD, dean and CEO of NYU Langone Health.

IOTAMOTION SURPASSES 125 USE CASES IN LIMITED MARKET RELEASE WITH EXPANSION OF CENTERS TO TAKE PLACE IN 2023

Retrieved on: 
Wednesday, February 1, 2023
De novo, Otorhinolaryngology, IOWA, Hand, Hospital, ASC, University of Utah Hospital, Dental implant, LMR, Patient, Hearing Health Foundation, Neurotology, University, 125th, Risk, FDA, Innovation, Multimedia, Ohio State University Wexner Medical Center, Surgeon, Contraindication, Cochlea, Hearing loss, Pharmaceutical industry, Medical device, MSCI, MD

Gaining authorization by FDA via a De Novo pathway in Q4 2021, iotaMotion began the Limited Market Release (LMR) of iotaSOFT in Q3 of 2022 at select centers across the country.

Key Points: 
  • Gaining authorization by FDA via a De Novo pathway in Q4 2021, iotaMotion began the Limited Market Release (LMR) of iotaSOFT in Q3 of 2022 at select centers across the country.
  • iotaMotion has leveraged this early release to garner initial feedback from surgeon partners, expand training, and build up internal support infrastructure.
  • With the LMR coming to a close, iotaMotion will continue to partner with these initial centers and expand into additional hospitals and ASC's in 2023.
  • iotaSOFT will expand to many top cochlear implant centers throughout the country as part of an expanded, controlled market release.

Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière's Disease

Retrieved on: 
Monday, January 9, 2023
Hearing loss, Deafness, National Institute on Deafness and Other Communication Disorders, Therapy, Principal, Neurotology, Inflammation, Division, SAN, Hearing, Patient, Medicine, Professor, Communication, Safety, UCSF, University, FDA, Medical school, Vertigo, Tinnitus, Pharmaceutical industry, Spiral

Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Ménière's disease.

Key Points: 
  • Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Ménière's disease.
  • A randomized, placebo-controlled Phase 2 clinical trial was initiated this month and will further investigate the safety and efficacy of SPT-2101 given as a single administration.
  • "The safety profile and clinical data from the initial SPT-2101 trial shows great promise for the unmet needs of people suffering from Ménière's disease."
  • "I am grateful to our investors for their support of Spiral over the years," said Hugo Peris, Founder and Chief Executive Officer of Spiral Therapeutics.

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

Retrieved on: 
Thursday, December 1, 2022
Optogenetics, Delaware General Corporation Law, Communication, LON, Retina, Life, Partnership, Patient, Central nervous system disease, Annual report, Neurotology, Eastern Time Zone, Central nervous system, CNS, Applied Genetic Technologies Corporation, Therapy, CVR, AAV, ACHM, Acquisition, Security (finance), Pharmaceutical industry

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).

Key Points: 
  • GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).
  • The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.
  • As a result of the merger, AGTC has become an indirect, wholly owned subsidiary of Syncona Limited.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

Retrieved on: 
Tuesday, November 29, 2022
Optogenetics, Communication, LON, Retina, TIME, Life, Partnership, Patient, Central nervous system disease, Neurotology, Eastern Time Zone, Computershare, Transmittal document, Schedule, Central nervous system, CNS, Security (finance), COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, CVR, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Pharmaceutical industry

The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022.

Key Points: 
  • The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022.
  • The tender offer was previously scheduled to expire at 5:00 p.m., Eastern Time, on November 28, 2022.
  • All other terms and conditions of the tender offer remain unchanged during the extension period.
  • The tender offer is being extended in order to allow additional time for shareholders to tender their shares and for shares tendered by notice of guaranteed delivery to be received.

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

Retrieved on: 
Monday, November 28, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

We urge you to tender your shares in the offer.

Key Points: 
  • We urge you to tender your shares in the offer.
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires TODAY, November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.

*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*

Retrieved on: 
Tuesday, November 22, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

We urge you to tender your shares in the offer.

Key Points: 
  • We urge you to tender your shares in the offer.
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.

Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022

Retrieved on: 
Monday, November 14, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.

Key Points: 
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.
  • Applied Genetic Technologies Corporation Contacts: